Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Core Insights - Buntanetap significantly improves cognition in Parkinson's patients, especially those with Alzheimer's co-pathology, showing a three-times greater response [1] - The treatment leads to reductions in plasma biomarkers pTau217, total tau, and brain-derived tau, indicating its potential to address cognitive decline and modify disease progression [1][4] - The findings support the need for therapies targeting multiple neurotoxic proteins, as neurodegenerative diseases often co-occur [3] Study Results - In a Phase 3 study, buntanetap halted cognitive decline in early Parkinson's patients, with the most significant improvements in those with mild dementia [2] - Approximately 25% of patients in the study exhibited amyloid co-pathology, which was associated with more pronounced cognitive decline that was counteracted by the treatment [2] Therapeutic Efficacy - Buntanetap treatment resulted in significant cognitive improvements in Parkinson's patients with amyloid co-pathology, supported by measurable reductions in established neurodegeneration biomarkers [4] - The data presented by the company is the first to explore treatment effects in Parkinson's patients with amyloid co-pathology, highlighting the drug's potential across multiple neurodegenerative diseases [5] Upcoming Presentation - Full biomarker data will be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in San Diego from December 1-4, 2025, with further details to be announced [5] Company Overview - Annovis Bio, Inc. is focused on developing innovative therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's, aiming to improve patient outcomes and quality of life [6]